Loading…
Loading…
SNSE (Sensei Biotherapeutics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
SNSE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SNSE and 80,000+ other tickers.
See exactly how SNSE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SNSE and 80,000+ other tickers.
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune response. They also employ the Tumor Microenvironment Activated Biologics (TMAB) platform. This system is engineered to unleash T-cells' anti-tumor capabilities, utilizing human monoclonal antibodies specifically designed to operate within the tumor's…
AUSTIN, Texas--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the “Company”). The Company's common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol “FTH” on June 16, 2026, and the Company has launched a new corporate website at www.faeththerapeutics.com. On June 10, 2026, stockholders approved the conversion of the Company's Series B preferred stock issued.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. â
BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors,” said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. “This ac.